Bausch Health soars on earnings beat and raised outlook

Investing.com -- Bausch Health Companies Inc. (NYSE: BHC) reported third quarter results that exceeded analyst expectations, with adjusted earnings per share of $1.77, beating the consensus estimate of $1.27 by $0.50. Revenue reached $2.94 billion, surpassing the $2.75 billion analyst estimate and marking a 10% increase from $2.68 billion in the same period last year.

Still guessing which stocks will beat the market? Our AI portfolio updates monthly and is outperforming the S&P 500 by 118%. See this month's list »

The company raised its full year 2026 revenue guidance to a range of $10.975 billion to $11.175 billion. The midpoint of $11.075 billion exceeds the analyst consensus of $10.924 billion. Bausch Health also increased its adjusted EBITDA guidance to $4.315 billion to $4.415 billion, representing projected growth of 12% to 14% versus the prior year.

Shares surged 12.5% in after-hours trading Wednesday following the announcement.

Unsure what to buy ahead of earnings? Our AI's recent pre-earnings calls delivered gains of +77% to +118% after results dropped. See this month's earnings picks »

"Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth," said Thomas J. Appio, Chief Executive Officer. "We also achieved an important milestone, with quarterly Adjusted EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time."

The Salix segment led growth with revenues of $831 million, up 16% from $716 million in the prior year period, driven primarily by Xifaxan, which posted 16% revenue growth. The Bausch + Lomb segment generated $1.38 billion in revenue, up 7% from $1.28 billion in the third quarter of 2025.

Consolidated adjusted EBITDA attributable to Bausch Health reached $1.305 billion, up 32% from $986 million in the prior year period. The company generated $813 million in cash from operating activities, more than double the $405 million produced in the third quarter of 2025.

The company's board authorized a $50 million share repurchase program intended to offset dilution from anticipated management equity award vesting in 2027.

Original Article

Bausch Health soars on earnings beat and raised outlook

Phillips 66 beats estimates on strong refining margins

Microsoft stock up over 2% after hours as Azure strength drives FQ1 results beat